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Abstract: 
Serum antibodies to Onchocerca volvulus native sodium duodecylsulphate slat  extracted antigens and 
epitopes recognized by three monoclonal antibodies designated Cam8, Cam22, and Cam28 were 
measured using indirect (sandwich) and competitive enzyme-linked immunosorbent assay (ELISA).  
Paired serum samples (n=32) were obtained before and two months post-ivermectin treatment.  Those 
with increases of ten percent and above (≥10%) were 16 (50%) for IgG, 13 (40.7%) for both IgG1 and 
IgG4.  Nine (28.2%) for IgM, eight (25%) for IgG3, IgA with four (12.5%) was the least, while IgG2 
was not assayed due to cross-reaction.  The higher increases in IgG, IgG1 and IgG4 antibodies in 
females (n=16) than males (n=16) were significant by T-test of unpaired data (P<0.05).  Those without 
onchocercal skin disease, OSD (n=18) had a significant increase of 20.5±29.6%, with pre- and post-
treatment values of 0.59±0.15 versus 0.68±0.13 for IgG antibody (P<0.05).  Both IgG1 and IgG4 
antibodies for those with OSD (n=14) increased by 16.0±24.8%.  Only IgG4 antibody increased with 
the presence of palpable nodule and higher skin microfilarial density.  Trend exhibited by Cam 22 and 
Cam 8 were similar to that of IgG and IgG4, respectively.  In conclusion, while IgG1 and IgG4 were 
both associated with skin diseases, IgG4 assay proved more suitable for onchocerciasis drug screening. 
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INTRODUCTION 
Onchocerciasis or river blindness is one 
of the main causes of preventable 
blindness in sub-Sahara Africa, 
including Nigeria.  Ivermectin® or 
Mectizan (a microfilaricide) is 
currently used for mass treatment of 
people in endemic areas.  This strategy 
is preferred to larvicides and adulticides 
formerly used for fly control, which 
have been abandoned because of the 
negative impact on environment.  
Infections were known to present with 
diverse clinical manifestations, even 
within the same organ.  The main trust 
of immunology is to identify immune 
responses involved in 
immunopathology and/or 
immunopathogenesis of the disease, the 
molecules (immunogens) that can 
induce protective immunity for vaccine 
production, and antigens useful for 
immunodiagnosis.  It has been 
suggested that it could serve as tool for 
drug screening and monitoring the 
efficacy of treatment (1).  In 
onchocerciasis, humoral and cell-
mediated immune (CMI) responses are 
widely reported to vary from one person 
to another (2).  Hence, the possible 
etiologic role particularly of parasite-
specific antibodies has remained poorly 
understood.  Understanding changes in 
immune responses after treatment in 
clinically defined patients could explain 
its secondary effects on pathology. 
Changes in polyclonal, and parasite 
specific antibodies, proliferative T 
lymphocyte, and cytokine production 
have been documented after ivermectin 
treatment (3, 4, & 5).  It has been 
postulated that immunologically 
mediated destruction of microfilariae 
could contribute to the pathogenesis of 
the disease.  Dying parasites initiate 
local inflammatory reactions, with the 
result of "bystander" tissue damage, 
which cumulatively determines host 
pathology (6 &7).  Absence of animal 
model precludes immunological studies; 
patients’ responses to therapy and risk 
factors for clinico-pathological changes 
in human infections are evaluated (8).  
However, Steel et al. (5) had shown that 
previously recognized and 
unrecognized parasite antigens were 
released into circulation. 
We report on the effect of ivermectin® 
on parasite antigen-specific serum 
antibodies two months post-initial 
treatment of individuals.  This type of 
study is useful for indirect quantitative 
assessment of B-lymphocyte anergy (or 
tolerance) to parasite antigens and to 
show if changes in antibodies were 
associated with gender, age, host 
parasite burden, and/or pathological 
sequel. 
Materials and methods 
Sample population 
After explaining to the participant in 
their dialect through an interpreter from 
the Local Government Area Health 
Department, full consent of individuals 
were obtained before been enlisted for  
this study. Serum samples were 
collected randomly from individuals 
(n=32) comprising 13 males and 19 
females that volunteered before initial 
ivermectin treatment was administered.  
Paired sera were obtained 2 months 
post-treatment.  The subjects varied in 
age with a Sample population mean and 
standard deviation (SD) of 39.9±15.2 and 
ranges between 15-69 years.  Sixteen of 
them had palpable nodule and the 
microfilarial density per skin snip was 
26.05±35.13 with a range of 0-141.  
Among them, those with at least one 
form of skin clinical signs were n=14 
and those without were n=18. 
Antigens  Detail method of preparing 
sodium duodecyl sulphate (SDS) 
extracted crude antigen has been 
described (9).  The extract was supplied 
to the immunology Research 
Laboratory, NITR, Kaduna as part of a 
collaborative study by Dr F. 
Engelbrecht, Heldelberge University, 
Germany then a Visiting Scientist. 
Monoclonal antibodies: 
Three monoclonal antibodies (mAbs) 
designated Cam 8, Cam 22 and Cam 28 
raised in mice were prepared by 
Engelbrecht et al., (9).  Only Cam 28 
has been characterized and found 
sensitive to periodate.  It reacts with 120 
KD molecular weight antigens.  These 
mAbs were provided by Dr F. 
Engelbrecht. 
SEROLOGY 
Serum samples were analyzed same day 
under similar assay conditions.  
Reactivity of serum antibodies with 
antigens and the three mAbs were tested 
with indirect and inhibition 
(competitive) ELISA, respectively.  
Indirect sandwich ELISA 
Immunoglobulin (Ig), IgA, IgM, IgG 
class and IgG1, IgG3 and IgG4 isotypes 
antibodies were measured using a 
modified protocol described by 
Engelbrecht et al., (9).  Briefly, microtitre 
plates were coated with antigens diluted 
in carbonate/bicarbonate buffer (pH9.6) 
at 1:100, and incubated overnight at 4°C. 
All other steps were performed at room 
temperature (RT°C).  The unspecific site 
were “blocked” with 200 µl per well of 
1-2% bovine serum albumin (BSA) for 1 
hour.  Serum was added at 1:80, 1:200, 
and 1:160 for IgA, IgG, and IgM 
reactivity to SDS extract.  Horseradish 
peroxidase conjugated to rabbit 
immunoglobulin anti-human IgG (Dako, 
Denmark) (code P214); IgM (P215) and 
IgA (P216) were applied at 1:1000, 1:400, 
and 1:500 diluted. 
For isotypes assays serum was added at 
1:500 for IgG1, 1:100 for IgG3 and 1:200 
for IgG4.  Thereafter, monoclonal 
antibody obtained from Sigma specific 
for each isotype, IgG1 (clone HP 6001, 
1:2000), IgG3 (HP 6050, 1:8000) and IgG4 
(HP 6025, 1:8000) were added at 150µl 
per well.  It was followed by goat anti-
mouse IgG (H+L) horseradish 
peroxidase conjugate (BIORAD) at 
1:1000 dilution. 
Antigen and antibody reactions were 
detected by addition of freshly prepared 
substrate solution containing 200µl 
orthophenylene diamine (OPD) (from 
Sigma) in 20µl hydrogen peroxide, 0.1M 
citric acid and 0.2M Na2HPO4 buffer 
and allowed to react for 15 minutes.  The 
enzyme reaction was terminated with 
30µl per wells 2M H2SO4 for 5 minutes.  
Optical densities (OD) of wells of 
microtitre plates were measured in a 
Dynatech ELISA reader (model MR4000) 
at 492nm-test filter and 630nm-reference 
filter. 
Inhibition (competitive) ELISA 
SDS extract was used at 1:1000 and 
serum at 1:50, for Cam 8, and 1:25 
dilutions for Cam 22 and Cam 28.  After 
the serum step, mAb was added at 1:25 
dilutions.  All subsequent steps were the 
same for isotype assay. 
Assay control 
Optimum concentration of antigens, 
serum, monoclonal antibodies, and 
conjugates were determined in a series 
of pre-titration experiments.  The final 
assays were performed in duplicate.  
Percentage inhibition was based on the 
difference between individuals mean 
OD-value and mean±2SD of the 16 
internal control blank wells. 
Statistical analyses 
 The means and standard deviation 
(mean±SD) for  absolute and percentage 
changes over pretreatment values for 
group or subgroup were tabulated.  The 
differences between pre-treatment and 
post-treatment values were subjected to 
t-test of paired and unpaired data. 
RESULTS 
Changes in ELISA antibodies after 
treatment  
Percentage increases in antibodies were 
calculated as the difference between 
baseline (pre-treatment) and follow-up 
(post-treatment) optical density (OD)-
values over the baseline value.  Among 
the antibody classes, the only 
remarkable increase was in IgG 
reactivity.  Similarly, the IgG subclasses 
had increases as shown on Table 1.  A 
change of ten percent and above (≥10%) 
were recorded in 16 individuals (50%), 
nine (28.2%) and four (12.5%) of the 
samples for IgG, IgM and IgA responses 
to SDS extract, respectively.  Among the 
three IgG isotypes, levels were enhanced 
in 13 (40.7%) patients for both IgG1 and 
IgG4, and 8 (25%) for IgG3.  The 
mean±SD of IgG, IgG1 and IgG4 
increased from 0.60±0.15, 0.42±0.11 and 
0.46±0.09 pre-treatment OD-values to 
0.68±0.14, 0.45±0.10 and 0.50±0.07 post-
treatment OD-values.  The increases 
represented a percentage change of 
15.1±24.9%, 11.1±22.5%, and 13.0±25.4%.  
On the contrary, decreases of ≥10% were 
recorded in 16 (50%) of the samples for 
IgA and 8 (25%) for IgM and 7 (22.0%) 
for IgG3. 
Analysis by sex and age 
 A significant increases in IgG, IgG1, and 
IgG4 antibodies in female subgroup 
(n=19) were higher than the male 
subgroup (n=13) as shown on Table 1 
(P<0.05).  Only IgG antibody showed an 
age dependent increase of 10.2±15.3% 
(0.62±0.16 vs 0.66±0.12) for those ≤40 
year (n=16). The 19.6±31.1% (0.58±0.14 
vs 0.69±0.16) for individuals ≥41 year 
old (n=16) was significant.  However, 
the differences between the two 
subgroups (≤40 year and ≥41 year old) 
were not statistically significant 
(P>0.05). 
Analysis of antibody changes by 
infection status 
There were no remarkable differences 
between pre- and post-treatment IgG 
and IgG1 levels. Only IgG4 antibody 
was significantly higher in the subgroup 
with (n=16) than without (n=16) 
palpable nodule (Table 2).  Presence of 
palpable nodule had affected IgM 
antibody increase in those with 
10.4±19% as against the 1.0±29.7% for 
those without nodule.  Similarly, only 
IgG4 antibody level was increased 
among persons having high skin 
microfilariae (≥16mf/snip, n=14)) 
compared to the subgroup with low skin 
mf (≤ 16mf/snip, n=18).  The percentage 
difference of 21.9±35.8% vs. 5.6±6.1%, 
respectively was statistically significant 
by t-test of unpaired data (P<0.05). 
Evaluation of binding of mAbs to 
worm extract 
The increased capacity of serum to 
inhibit binding of three monoclonal 
antibodies designated Cam 8, Cam 22, 
and Cam 28 to SDS extract was 
evaluated.  The mean±SD of OD-values 
before and after treatment were 
0.21±0.04 vs. 0.19±0.06) for Cam 8, with 
0.39±0.12 vs. 0.34±0.14 for Cam 22 and 
no change in serum inhibition of Cam 28 
(0.31±0.10).  Post-treatment changes in 
serum inhibition of ≥10% occurred in 13 
(40.7%) for Cam 8, with Cam 22 having 
15 (48%  
 
Effect of onchocercal skin disease on 
antibody levels 
Presence of onchocercal skin disease 
(OSD) in individuals influenced the 
levels of antibodies.  Table 3 shows that 
those presenting with OSD (n=14) had 
increased IgG1 and IgG4 than those 
without OSD (n=18).  The reverse was 
the case for IgG antibody with a 
mean+SD percentage change of 
20.5±29.5% and 7.7±13.9% for those 
without OSD compared to those having 
OSD.  A change in IgG mean±SD of OD-
values before and after treatment from 
0.59±0.15 to 0.68+0.13, was statistically 




 Cam 28 had 8 (25%) of the samples 
(n=32).  An age dependent increase in 
inhibition of Cam 22 was recorded, but 
not statistically significant (P>0.05).  In 
addition, the difference was influenced 
by presence of nodule and number of 
skin microfilariae.  Increase in Cam 22 
inhibition was more in subgroup 
without OSD compared to Cam 8 that 
had higher increase in the subgroup 
having OSD.  
 









Pre-dose (n=32) 0.55±0.15 0.39±0.11 0.43±0.10 
Post-dose 0.65±0.16 0.44±0.12 0.49±0.08 
Percentage changes (%) 20.5±28.4* 19.0±25.4* 18.2±30.6* 
    
 


































Post-dose 0.65±0.16 0.44±0.12 0.49±0.08 
 
% changes 18.63±29.16* 18.6±25.5** 18.5±31.0** 
 
 
Note: *Observed intra difference within a subgroup (pre-dose vs post-dose) and **inter differences between 
subgroups (male and female) were statistically significant (P<0.05) by t-tests of paired and unpaired data, 
respectively.  SD= standard deviation. 
 













































Post-dose 0.70±0.11 0.48±0.10 0.52±0.04 
 




Note: * Intra differences in antibody levels were statistically significant (P<0.05) by t-test of paired data.  
The –ve = negative and +ve = positive subgroups 












Without OSD (n=18) 
Before treatment   
 
0.59 ± 0.15 
 
0.41 ± 0.11 
 





0.67 ± 0.12 
 
0.43 ± 0.11 
 





20.5 ± 29.6* 
 
7.0 ± 19.7 
 
8.0 ± 11.4 
 
With OSD (n=14) 
Before treatment 
 
0.63 ± 0.14 
 
0.43 ± 0.12 
 





0.68 ± 0.16 
 
0.47 ± 0.10 
 





7.7 ± 13.9 
 
16.0 ± 24.8* 
 
18.8 ± 35.4* 
 
 
Note: OSD= Onchocercal skin diseases. *The intra differences were statistically significant (P<0.05) by t-test 




Antibodies to O. vulvulus adult worm extract 
were quantified in ELISA in same patients’ 
(n=32) paired sera taken before and two 
months after initial ivermectin dosing.  
Appreciable increase in antibody levels that 
were observed in some and not in others 
only confirmed the variability within an 
individual, and individual differences in 
immune response to onchocerciasis infection  
 
 
(6).  The poor performance of IgA followed 
by IgM and IgG3 antibodies clearly point to 
non-stimulation or specific tolerance by 
many infected individuals.  Other 
possibilities include the fact that IgA and 
IgM have relatively shorter half-life and they 
are produced in low concentration.  While 
IgM is  mainly a primary response compared 
to the secondary or anamnestic response 
induced by ivermectin treatment.  In 
addition, the rates at which the three 
antibodies were catabolised must have by far 
outweighed the rates of their syntheses.  The 
combination of these factors is strongly 
believed to underlie the decreases recorded 
for the three antibodies.  Yet, no remarkable 
trend was exhibited by the observed 
decline.The enhanced antibody titers in 
females than the males following treatment 
could not be explained.  Whether this 
connoted gender difference in 
immunological reaction to the drug calls for 
further investigation. For long, gender 
related differences to infection, immune 
responses, and clinical manifestations have 
all been suspected.  Our data clearly showed 
that parasite materials librated after 
ivermectin treatment evokes variable 
secondary or anamnestic responses resulting 
from antigenic stimulation. 
A large number of microfilariae from 
superficial layers of skin were reported 
to be sequestered into deeper connective 
tissues, fats and lymph node following 
treatment (10).  This might be one reason 
why vigorous responses do not 
accompany ivermectin treatment.  
Previous research works undertaken 
along this line have shown changes in 
qualitative immunoblot analyses of IgG 
and IgE antibody to previously 
recognized and unrecognized antigens, 
which occurred in 50% and one third of 
the patients, respectively.  Others (3) had 
observed the same frequency of 
antibody change two weeks after 
diethylcarbamazine (DEC) and 
ivermectin treatment, respectively.  
From our study, a similar quantitative 
trend two months post-treatment was 
established in which 50% of 
onchocerciasis patients presented with 
antigen-specific immune response.  
Whether the observed increases in 
antibodies provoke concomitant 
immunity in those individuals remains a 
matter of conjecture. 
On the contrary, the other specter of 
individuals exhibited immune 
unresponsiveness or tolerance.  Reports 
showed that acquisition of O. volvulus 
could not occur constantly over time, 
which strongly emphasize the 
importance of immunosuppressive 
processes in man.  Suppression of 
parasite-specific immunity leads to 
parasite establishment rates, which 
increase along with the parasite burden 
(11).  Therefore, we can only speculate 
that there was B-cell tolerance to 
antigens released after treatment, since 
not all individuals responded with 
increased antibodies.  Normally, if 
antigen is present in high enough 
concentration for a long period it is 
possible for immune tolerance be 
induced following a state of specific 
immunity (12).  In chronic infection, 
clonal exhaustion may diminish the 
capacity of immune system to respond 
following treatment (3).  Circulating 
antigens that form complexes with 
antibodies in onchocerciasis (1 & 13) 
were capable of inducing some form of 
tolerance.  All these notwithstanding, 
what remains unclear are whether the 
assumed state of tolerance involved T-
lymphocytes in clonal elimination or 
blocking.  Already, Steel et al., (5) have 
shown that T cell proliferative response 
was enhanced 6 months after ivermectin 
treatment but reverted back to 
pretreatment values in 1year. It is very 
likely that the adult worm extract used 
contains mostly low molecular weight 
(LMW) antigens (9).  The antigens could 
be either proteins or polysaccharide-
protein complexes that can provoke T-
dependent antibody responses. 
The remarkable increases in IgG4 
antibody associated with infection 
intensity based on skin microfilaria 
density and palpable nodule were 
statistically significant (P<0.05).  The 
increase was apparently in agreement 
with earlier reports correlating the levels 
of this isotype with parasite burden (14-
15).  It seems IgG4 is a likely candidate 
of choice for antibody assays for drug 
screening.  Again, it plays the role of 
blocking hypersensitivity reaction 
induced by IgE and preventing 
microfilaria clearance as well (7, 16, 17 & 
18).  Earlier work by Whitworth et al., 
(19) showed there was no reduction in 
itching 2 months after initial ivermectin 
treatment.  Higher increases in IgG1 and 
IgG4 antibody level of patients having 
skin diseases support the fact that 
hypersensitivity induced by the former 
is unaffected by immune blockade of the 
later. 
Among the three mAbs, only Cam 22 
showed an appreciable overall increase 
in percentage inhibition.  The observed 
increases in older age (≥41years) and 
palpable nodule positive subgroups 
compared with those of younger age 
(≤40years) and palpable nodule negative 
subgroups respectively, were not 
statistically significant (P>0.05).  
Important inferences from this study are 
(i) the gender sensitivity to antibody 
changes, (ii) association of IgG1 and 
IgG4 with skin disease, and (iii) the 
potential of  IgG4 indirect and Cam 22 
competitive ELISA for drug screening.  
In addition, the studies showed there 
was selective unresponsiveness to 
antigenic epitopes defined by the mAbs. 
In future, this type of study will become 
difficult to carry out, since most endemic 
areas would have been covered by the 
on-going community directed treatment 
of onchocerciasis with ivermectin. 
Acknowledgements 
We thank Dr. I. Halid, the then Director-
General, NITR, for approving fund for 
this project.  We appreciate the inputs 
from European Economic Community 
(EEC) grant to Dr. Edeghere.  We thank 
Mr. Peter Damboi the Ophthalmic 
Nurse, formerly of National Eye Centre, 
Kaduna, Mal. M.S Mohammed, the 
Rural Health Superintendent and Mr. 
James Gazama, Technical Assistant from 
NITR for their various roles in the 
project. 
References 
1 More, S.J. and Copeman, D.B. (1991).  
The use of monoclonal antibody      based 
ELISA to monitor the efficacy of drugs 
against male O. gibsoni in vitro.  Trop. Med. 
Parasitol.  42: 21-24. 
 2King, C.L. and Nutman, T.B.  (1991). 
Regulation of immune responses in 
lymphatic filariasis and onchocerciasis.  
Immunol.  Today.  March12, A54-58. 
3Lee, S.J., Francis, H.L., Awadzi, K, 
Ottesen, E.A. and Nutman, T.B. (1990).  
Changes in antibody profile after 
treatment of human onchocerciasis.  J. 
Inf. Dis. 162: 529-533. 
4.Steel, C., Lujan, T.A., Gonzalez Peralta, 
C., Zea Flores, G. and Nutman, T.B. 
(1991).  Immunological responses to 
repeated ivermectin treatment in-
patients with onchocerciasis.  J. Inf. Dis. 
164: 581-587. 
5.Luty, A.J.F., Downham, M.D., 
Withworth, J.A.G., Morgan, D. and 
Taylor, D.W. (1992).  Immunological 
studies on onchocerciasis in Sierra 
Leone.  2. Cell-mediated immune 
responses after repeated treatment with 
ivermectin. 
6.Mackenzie, C.D., Williams, J.F., 
Guderian, R.H. and O’Day, J. (1985). 
Variations in host responses and the 
pathogenesis of human onchocerciassis.  
Rev. Infec.  Dis.  7: 802-807. 
7.Ottesen EA (1995).  Immune 
responsiveness and the pathogenesis of 
human onchocerciasis.  J Infect Dis. Mar. 
171(3): 659-761. 
8.  World Health Organization (WHO, 
1988).  Report of the steering committee 
of the scientific Working Group on 
filariasis (unpublished data).  
TDR/FIL/SC-SWG (83-88)/88.3.pp150. 
9Engelbrecht, F., Eisenhardt, G., Turner, 
J., Sundaralingam, J., Owen, D., Braun, 
G., Connor, D.W. (1992).  Analysis of 
antibody responses directed against two 
O. volvulus antigens defined by 
monoclonal antibodies.  Trop. Med. 
Parasit.  43: 47-53. 
10Darge, K, Lucius, R, Monson, MH, 
Behrendsen, J and Buttner, DW (1991).  
Immunological and electron microscopic 
studies of microfilariae in skin and 
lymph nodes from onchocerciasis 
patients after ivermectin treatment.  
Trop. Med. Parasitol.  42: 361-367. 
11.Duerr, H, Dietz1, K, Schulz-Key, H, 
Büttner, DW, and Eichner, M (2003) 
Density-dependent parasite 
establishment suggests infection-
associated immunosuppression as an 
important mechanism for parasite 
density regulation in onchocerciasis.  
Trans. R. Soc. Trop. Med. Hyg.  97: 242-
50. 
12.Wigzell, H. (1985) Immune tolerance 
and autoimmunity.  In Immunology.  
(Editor)  Hanson, LA and Wigzell, H 
Butterworth, London.Ch 8, 90-99. 
13.Chamdrachekar, R., Ogunriade, A.F., 
Alvarez, RM, Kale, O.O. and Weil, G.J. 
(1990).  Circulating immune complex 
associated parasite antigens in human 
onchocerciasis.  J. Inf. Dis. 62: 1159-1164. 
14.Ottesen, E.A., Skvaril, F., Tripathy, 
S.P., Poitdexter, R.W. and Hussain, R. 
(1985). Prominence of IgG4 in the IgG 
antibody response to human filariasis. J. 
Immunol. 134: 2707-2712. 
15.Ottesen, E.A., Kumaraswami, V., 
Parnjape, R., Poidexter, R.W. and 
Tripathy, S.P.  (1981) Naturally 
occurring blocking antibodies modulate 
immediate hypersensitivity responses in 
human filariasis.  J. Immunol.  134: 2014-
2019. 
16.Ottesen, E.A., Kumaraswami, V., 
Parnjape, R., Poidexter, R.W. and 
Tripathy, S.P.  (1981). Naturally 
occurring blocking antibodies modulate 
immediate hypersensitivity responses in 
human filariasis.  J. Immunol.  134: 2014-
2019. 
17.Egwang, TG, Nguiri, C, Kombila, M, 
Duong, TH, Richard Lenoble, D.  
Elevated antifilarial IgG4 antibody levels 
in microfilaremic and microfilaridermic 
Garbonese adults and children.  Am. J. 
Trop. Med Hyg. (1993) 49(1): 135-142. 
18.Hussain, R., Poitdexter, R.W. and 
Ottesen, E.A. (1992).  Control of allergic 
reactivity in human filariasis.  
Prodominant localization of blocking 
antibody to the IgG subclass.  J. 
Immunol.  148(9): 2731-2737. 
19.Whitworth, JA, Luty, AJ, Maude, GH, 
Morgan, D, Downham, MD and Yaylor, 
DW. (1992). Ivermectin does not reduce 
the burden of itching in an 
onchocerciasis endemic community. 
Trans. R. Soc.Trop. Med. Hyg. 86(3): 281-
283. 
 
 
 
 
 
 
 
 
 
 
 
 
